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ABSTRACT
Retention of androgen receptor (AR) signalling in castrate-resistant prostate cancer 
(CRPC) highlights the requirement for the development of more effective AR targeting 
therapies. A key mechanism of resistance to anti-androgens is through expression 
of constitutively active AR variants (AR-Vs) that are refractory to next-generation 
therapies, including Enzalutamide and Abiraterone. By maintaining an androgenic gene 
signature, AR-Vs drive tumour survival and progression in castrate conditions. Critically, 
however, our understanding of the mechanics of AR-V-driven transcription is limited, 
particularly with respect to dependency on pioneer factor function. Here we show that 
depletion of FOXA1 in the CWR22Rv1 CRPC cell line abrogates the oncogenic potential 
of AR-Vs. Gene expression profiling reveals that approximately 41% of the AR-V 
transcriptome requires FOXA1 and that depletion of FOXA1 attenuates AR-V binding at 
a sub-set of analysed co-regulated genes. Interestingly, AR-V levels are elevated in cells 
depleted of FOXA1 as a consequence of attenuated negative feedback on the AR gene, 
but is insufficient to maintain cell growth as evidenced by marked anti-proliferative 
effects in FOXA1 knockdown cells. In all, our data suggests that AR-Vs are dependent 
on FOXA1 for sustaining a pro-proliferative gene signature and agents targeting FOXA1 
may represent novel therapeutic options for CRPC patients.
INTRODUCTION
Prostate cancer (PC) is the most prevalent male 
cancer in the Western world and represents the fourth 
most common cancer worldwide. PC growth is initially 
androgen-dependent hence the mainstay for treatment is 
hormone-ablation therapy using anti-androgens and/or 
androgen-deprivation therapies (ADT) [1, 2]. Unfortunately, 
in most patients, efficacy of these treatments is short-lived 
and the cancer typically recurs in a more aggressive form, 
termed castrate-resistant prostate cancer (CRPC), that 
remains challenging to treat and is largely fatal [3]. The 
development of second generation anti-androgen therapies, 
such as Enzalutamide [4, 5] and abiraterone [6, 7], have 
shown promise in the treatment of CRPC, but are not 
effective in all patients and the development of resistance 
has limited their success in the clinic [8, 9].
The androgen receptor (AR) is a member of the 
nuclear hormone receptor family of transcription factors 
that transmits androgenic signals to drive prostate growth 
and cellular transformation. Like other nuclear receptors, 
the process of AR-mediated transcription is complex and is 
tightly orchestrated within the nucleus by a plethora of co-
regulatory proteins, a number of which directly acetylate and 
methylate the receptor to control the strength and duration 
of androgenic signalling [10–13]. Our understanding 
of the global functionality of the AR as a DNA-binding 
transcription regulator has been re-defined over the past 
number of years with the demonstration that additional 
transcription factors, such as FOXA1, control AR-chromatin 
deposition and are instrumental in controlling receptor-
driven tissue-specific transcriptional programmes [14, 15]. 
Several independent studies have shown considerable 
overlap between ligand-inducible AR and FOXA1 DNA-
binding sites within both proximal promoter and distal 
enhancer elements of target genes suggesting a pioneering 
role for FOXA1 in facilitating receptor-mediated gene 
expression [16–18]. Intriguingly, however, depletion of 
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FOXA1 in several PC cell lines is not deleterious to all AR 
binding events at shared androgen response element (ARE) 
and FOXA1-binding sites, and a concurrent stimulation of 
receptor binding to new AREs within the genome suggest 
that FOXA1 may function to both facilitate and repress AR 
signalling at discriminate genomic loci [16, 19].
Several aberrations in the AR signalling cascade 
have been identified in CRPC, including AR mutation and 
non-androgenic activation of the receptor, that facilitate 
AR activity in castrate conditions and contribute to 
conventional and next-generation anti-androgen treatment 
failure [20, 21]. More recently, the identification of novel 
AR variants in CRPC that are refractory to hormonal 
therapies has provided an additional avenue for treatment 
evasion and progression to advanced disease [22, 23]. AR 
variants (termed AR-Vs), such as the clinically-relevant 
AR-V7 protein, lack the conventional C-terminal ligand-
binding domain (LBD), but retain the potent N-terminal 
transactivation domain and DNA-binding domain, and 
are thus capable of driving the androgenic signalling 
programme in castrate conditions and remain unchallenged 
by the current repertoire of receptor-targeting agents [24, 
25]. Moreover, although splicing aberrations have been 
shown to be responsible for the generation of several 
AR-Vs in PC cell-line models, such as CWR22Rv1 and 
VCaP, and patient samples of CRPC [26, 27], there is 
clear evidence that genomic deletion of exons coding the 
LBD is an additional mechanism of AR-V production in 
advanced disease [28]. Importantly, both experimental and 
translational analyses indicates overexpression of AR-Vs 
in approximately 50%–60% of CRPC patients with the 
figure rising further in metastatic disease [29].
Our understanding of how AR-Vs are regulated 
remains limited, particularly with respect to their 
dependency on pioneer factors for transcriptional activity. 
To this end, we assessed the role of FOXA1 in regulation 
of AR-Vs in CWR22Rv1 cells and show that 41% of the 
AR-V transcriptome overlaps with a FOXA1-dependent 
gene signature. Consistent with previous findings in 
LNCaP cells [19], depletion of FOXA1 in CWR22Rv1 
cells up-regulates several genes, including PSA and 
KLK2, that is a direct consequence of elevated AR-V 
levels. Irrespective of this, however, FOXA1 knockdown 
markedly reduces cell growth and is shown to be an 
important regulator of the pro-proliferative function of 
AR-Vs in CRPC. In all, our data supports the notion that 
AR-V activity is regulated by pioneer factors akin to the 
full-length AR (FL-AR), and FOXA1 may represent a 
suitable target for therapy in advanced disease.
RESULTS
AR-Vs are constitutively chromatin bound and 
refractory to enzalutamide
The ability for AR-Vs to confer resistance to current 
and next-generation ADT and anti-androgens is well 
established and is likely a result of constitutive activation 
of an androgenic signalling programme refractory to AR-
targeted agents [27]. However, our understanding of the 
chromatin-binding kinetics and transcriptional requirements 
of AR-Vs in CRPC is very limited. To this end, we firstly 
assessed the recruitment of AR-Vs to several known AR 
target genes in CWR22Rv1 cells, that express very high 
levels of receptor variants, and compared binding profiles 
to that of the FL-AR in both CWR22Rv1 and VCaP cells. 
Consistent with the effect of Enzalutamide as a LBD-
targeting agent [30], chromatin immunoprecipitation (ChIP) 
experiments, using a C-terminal-targeting AR antibody 
(C-19), demonstrate that FL-AR is depleted from the PSA 
enhancer in both VCaP and CWR22Rv1 cells (Figure 1A). 
Importantly, however, an antibody targeting an N-terminal 
receptor epitope (AR N-20) shows that chromatin binding 
of the AR is retained upon both Enzalutamide treatment 
and specific depletion of FL-AR in CWR22Rv1 cells 
suggesting AR-variants are constitutively bound to 
chromatin (Figure 1B and Supplementary Figure S1). In 
contrast, although VCaP cells express a population of AR-
Vs, the levels are considerably lower than CWR22Rv1 cells 
and this is reflected in the marked reduction in AR binding 
at the PSA enhancer in response to anti-androgen treatment.
To confirm constitutive AR-V-DNA binding 
interaction, chromatin extractions were performed in 
CWR22Rv1 cells grown in the presence and absence 
of 10 nM DHT with and without 1 μM Bicalutamide or 
Enzalutamide. As shown in Figure 1C, levels of chromatin-
bound FL-AR are elevated upon DHT stimulation and 
reduced upon treatment with anti-androgens. In keeping 
with the ChIP data, however, AR-Vs were found to be 
constitutively chromatin bound irrespective of hormonal 
or anti-androgen status suggesting that AR-Vs have the 
potential to retain androgenic signalling by mediating 
robust DNA-binding activity in cells. This finding was 
supported further using formaldehyde-assisted isolation 
of response elements (FAIRE) in both FL-AR-expressing 
LNCaP cells and CWR22Rv1 cells. As shown in 
Figure 1D, unlike LNCaP cells which displayed increased 
chromatin relaxation at cis-regulatory elements within the 
PSA enhancer and TMPRSS2 promoter in response to DHT 
treatment that reflects recruitment of FL-AR to these loci, 
AR-V expressing CWR22Rv1 displayed a consistently 
open chromatin conformation in the absence of androgen 
indicating the presence of a constitutively-bound AR-V 
population (Figure 1E). Intriguingly, in response to DHT 
treatment, cis-regulatory elements of PSA and TMPRSS2 
genes was compacted by hormone treatment suggesting that 
activation of FL-AR may counteract chromatin opening by 
AR-Vs although this needs to be fully evaluated.
FOXA1 depletion elevates PSA, KLK2 and 
AR-V mRNA in CWR22Rv1 cells
Given that FOXA1 is instrumental in regulating 
FL-AR chromatin deposition at discriminate androgenic 
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cistromes [16, 19, 31], it is conceivable that FOXA1 
may co-operate with AR-Vs to facilitate their role as 
oncogenic drivers in advanced PC. Our demonstration 
that AR-Vs are constitutively chromatin bound in 
CWR22Rv1 cells provided an indication that interplay 
between FOXA1 and receptor variants may exist. We 
therefore firstly assessed the impact of FOXA1 depletion 
on the AR-target genes PSA and KLK2 in CWR22Rv1 
cells as both have been shown to be regulated by the 
pioneer factor in PC cells [19] As expected, PSA 
and KLK2 expression was refractory to 10 nM DHT 
stimulation due to their transcription being largely 
driven by AR-Vs (Figure 2A and Supplementary Figure 
S2). Importantly, FOXA1 knockdown markedly elevated 
expression of both PSA and KLK2 in the presence and 
absence of 1 nM and 10 nM DHT, a finding that is 
consistent with reports describing FOXA1 as a regulator 
of FL-AR activity [19]. Furthermore, Enzalutamide 
treatment failed to reduce PSA and KLK2 expression 
suggesting that this phenomenon was driven by AR-Vs; 
a finding supported by receptor knockdown ( Figure 2B).
Given that both AR target genes were 
overexpressed in conditions where only AR variants are 
likely to be functional, we hypothesised that FOXA1 
regulated expression of these receptor isoforms. 
As shown in Figure 3, FOXA1 depletion increased 
mRNA expression of both AR-V7 and AR-1/2/3/2b 
in CWR22Rv1 cells (Figure 3A), but not the FL-
AR (Figure 3B) and this was confirmed at the protein 
level using anti-AR-V7 and AR (N-20) antibodies 
(Figure 3C). Importantly, increased AR variant 
levels persisted in the presence of Enzalutamide 
(Figure 2C  and Figure 3D) and is consistent with 
a role for the AR-Vs in driving up-regulation of PSA 
and KLK2 in FOXA1 knockdown cells. This data was 
confirmed using additional FOXA1-targeting siRNAs 
(Supplementary Figures S3 and S4).
FOXA1 regulates AR-V expression through an 
AR gene repressor element
The existence of an androgenic downstream 
repressor element (DRE) in intron 2 of the AR gene has 
been shown to control receptor expression in VCaP cells 
[32]. By recruiting the histone methyltransferase LSD1 to 
this loci in response to DHT, the receptor down-regulates 
Figure 1: AR-Vs are constitutively chromatin bound. Chromatin immunoprecipitation (ChIP) was performed using AR (C-19) 
A. or AR (N-20) B. antibodies in VCaP and CWR22Rv1 cells treated with 10 nM DHT or 1 μM Enzalutamide for 4 hours and AR recruitment 
to the PSA enhancer element was analysed by quantitative PCR. C. Chromatin fractionation was performed in CWR22Rv1 cells treated as 
above and resultant samples were subject to anti-AR, PARP1 (chromatin) and α-tubulin (cytoplasmic) antibodies. Formaldehyde-assisted 
isolation of response elements (FAIRE) was performed in LNCaP D. and CWR22Rv1 E. cells after 4 hours 10 nM DHT treatment and 
resultant DNA was analysed by quantitative PCR using primers specific to the indicated genes. All data represents the mean of at least three 
independent experiments +/− SE (*denotes p-value < 0.05)
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AR gene transcription through demethylating histone H3 
lysine 4 at upstream cis-regulatory elements. As shown 
in Supplementary Figure S5A, we have confirmed that 
active FL-AR is recruited to two regions of the DRE 
(Intron 2A and 2B) in VCaP cells that is attenuated in 
the presence of Enzalutamide. Moreover, exposure of 
VCaP cells to 10 nM DHT markedly reduced AR-V7 
levels (Supplementary Figure S5B), indicating that 
AR variant expression is also under the control of this 
phenomenon and is consistent with recently published 
data [33]. Although not as robust as VCaP cells, reduced 
AR-V7 and AR-1/2/3/2b expression in response to DHT 
was also demonstrated in CWR22Rv1 cells depleted of 
FOXA1 (Figure 3A), suggesting the same auto-regulatory 
loop exists for AR-V regulation in an additional model of 
advanced CRPC. From these indications, we reasoned that 
AR-V expression in CWR22Rv1 cells is self-limiting and 
FOXA1 may function to facilitate AR deposition at this 
DRE and down-regulate total AR mRNA levels. Therefore, 
we first sought to establish if the DRE bound both AR and 
FOXA1 in CWR22Rv1 cells. ChIP experiments using the 
AR (N-20) antibody demonstrated enrichment of receptor 
species above IgG control even in the absence of DHT 
(Figure 4A) suggesting that AR-Vs are constitutively 
bound to this site, but not to a control intron 2 region 
(Supplementary Figure S6A). Consistent with AR binding, 
FOXA1 was enriched at the DRE (Figure 4B) albeit 
to lower levels than the PSA promoter (Supplementary 
Figure S6B) and was not affected by Enzalutamide 
(Figure 4C). To assess the role of FOXA1 in regulating 
AR-V recruitment to the AR gene DRE, we depleted 
FOXA1 in CWR22Rv1 cells and demonstrated that this 
markedly reduced both FOXA1 and AR-V enrichment at 
the repressive cis-regulatory element (Figures 4C and 4D), 
and the PSA promoter (Supplementary Figure S7A), but not 
at a control DRE element (Supplementary Figure S7B). Our 
findings demonstrate pertinent interplay between FOXA1 
and AR-Vs for controlling receptor variant expression and 
provide a mechanistic insight into the observed elevation of 
AR-Vs in response to pioneer factor knockdown in CRPC.
FOXA1 regulates AR-V activity
In order to establish a role for FOXA1 in regulating 
global AR-V transcriptional activity, we individually 
depleted AR and FOXA1 in CWR22Rv1 cells grown in 
Figure 2: FOXA1 depletion up-regulates PSA and KLK2 expression in CWR22Rv1 cells. A. FOXA1 levels were reduced by 
siRNA knockdown for 48 hours in CWR22Rv1 cells and expression of PSA and KLK2 was measured after 24 hours 10 nM DHT stimulation 
by quantitative PCR. Representative FOXA1 protein levels are shown on the right. B. As in (A), but with the inclusion of a 1 μM Enzalutamide 
treatment arm for 24 hours prior to quantitative analysis. C. AR and FOXA1 knockdown is confirmed by immunoblotting using anti-
AR and –FOXA1 antibodies. All data represents the mean of at least three independent experiments +/− SE (*denotes p-value < 0.05)
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the presence of Enzalutamide and assessed differential 
gene expression signatures in both experimental arms. To 
confirm that the effect of AR knockdown was a specific 
read-out for AR-V function, we firstly conducted analysis 
on CWR22Rv1 cells grown in steroid-depleted conditions 
with and without Enzalutamide to assess the activation 
status of FL-AR in these conditions. Importantly, we 
found that maintaining cells in the absence of DHT for 
72 hours was sufficient to completely abrogate FL-AR 
activity as treatment with Enzalutamide failed to impact 
on global gene expression (data not shown). We therefore 
reasoned that all genes found to be de-regulated upon AR 
knockdown can be attributed to AR-V activity. In support 
of this, Figure 1C demonstrates low levels of FL-AR 
bound to chromatin in androgen-depleted conditions 
suggesting compromised FL-AR signalling.
Depletion of AR and FOXA1 resulted in 
differential expression of respective 3085 and 2224 
probes (Supplementary Tables S1 and S2), equating 
to 2366 and 1722 annotated genes (Supplementary 
Figure S8) with 41% of AR-V target genes demonstrating 
overlap with FOXA1; and 56% of the FOXA1 
transcriptome being dually controlled by AR-Vs. 
Of those genes demonstrating a significant 1.5-fold 
up- (382 genes) and down-regulation (440 genes) in 
response to AR-V depletion, 30% and 39% respectively, 
were also found to be similarly up- and down-regulated 
by FOXA1 (Figures 5A), suggesting a considerable 
overlap in functionality of the two proteins in AR-V-
mediated signalling.
Several studies have suggested AR-Vs regulate 
a distinct gene-set to that of FL-AR; including a 25 
gene signature, including UBE2C, that was defined as 
being specifically up-regulated by ectopically-expressed 
AR-V7 in LNCaP cells (termed AR-V7 UP, [34]). 
Integrating our AR-V-activated transcriptome data 
(siAR DOWN) with this LNCaP-derived AR-V7 UP 
signature identified an overlap of 20 out of 25 genes 
(80%) (Supplementary Figures S9A and S9C) suggesting 
concordant activity of variants in distinct cellular 
backgrounds. Additionally, we identified 13 out of 25 
(52%) AR-V7 UP genes to be regulated by AR-V and 
FOXA1 in CWR22Rv1 cells (Supplementary Figures S9B 
and S9C) supporting the concept that pioneer activity is 
important for variant-mediated transcription.
A recent and more physiological study identified 
a total of 285 non-duplicated probes to be up-regulated 
by AR-Vs in CWR22Rv1 cells [35]. Comparison with 
our AR-V signature demonstrated an overlap of 20% 
(Supplementary Table S3), and importantly, 49% of these 
genes were co-regulated by FOXA1 indicating a robust 
overlap in functionality of the pioneer factor and receptor 
variants (Supplementary Table S4).
To further validate FOXA1 as a regulator of AR-V 
activity, we focussed on the genes UBE2C, NKx3.1 and 
ATAD2 that were identified from the micro-array as 
Figure 3: FOXA1 knockdown elevates AR-V expression in CWR22Rv1 cells. A. FOXA1 was depleted by siRNA for 48 hours 
in CWR22Rv1 cells and levels of AR-V7, AR-1/2/3/2b were measured after 24 hours 10 nM DHT stimulation by quantitative PCR. B. As 
in (A), but cells were additionally depleted of AR by siRNA and treated for 24 hours with Enzalutamide prior to analysis of FL-AR mRNA. 
C. Western analysis of FOXA1 knockdown samples using AR (N-20), AR-V7, FOXA1 and α-Tubulin antibodies. D. As in (A) but with the 
inclusion of a 1 μM Enzalutamide treatment arm. All data represents the mean of at least three independent experiments +/− SE (*denotes 
p-value < 0.05)
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being down-regulated in response to FOXA1 and AR 
knockdown. As shown in Figure 5B and Supplementary 
Figure S10, each gene was robustly down-regulated 
in response to FOXA1, AR and AR-V depletion using 
specific siRNA oligonucleotides and this occurred 
irrespective of DHT dose (Supplementary Figure S11). 
Interestingly, UBE2C and ATAD2 expression was 
modestly elevated in response to Enzalutamide, 
suggesting that FL-AR may act to repress the function 
of AR-Vs at these genes (Figure 5B). ChIP experiments 
in CWR22Rv1 cells depleted of FOXA1 showed robust 
reduction in AR-V recruitment to a cis-regulatory 
element of the UBE2C gene indicating dependency of 
FOXA1 for receptor variant target gene recruitment 
and transcriptional output (Figure 5C). To confirm 
that the predominant AR species at the these promoter 
elements are AR-Vs, we specifically depleted FL-AR 
using an exon 4-targeting siRNA and demonstrated no 
loss of receptor retention (Supplementary Figure S12). 
Intriguingly, the effect of attenuated AR-V promoter 
association is not recapitulated globally; chromatin 
extractions from CWR22Rv1 cells depleted of FOXA1 
demonstrate increased chromatin association of AR-Vs, 
and specifically AR-V7, that is likely a consequence 
of elevated protein levels in FOXA1 knockdown cells 
(Supplementary Figure S13).
FOXA1 regulates pro-proliferative activity of 
AR-Vs
Applying gene set enrichment (GSE) analysis 
(using Database for Annotation, Visualization and 
Integrated Discovery (DAVID)) to our AR-V and 
FOXA1-co-regulated genes identified cell cycle 
control as the highest-ranked pathways dually 
controlled by AR-V and FOXA1 (Figure 6A). Cyclin 
A2 (CCNA2), Cyclin B1 (CCNB1), Cyclin E2 (CCNE2) 
and Cyclin-dependent Kinase 1 (CDK1) were all 
found to be significantly down-regulated in response 
to individual depletion of AR and FOXA1, indicating 
a role for FOXA1 in controlling the activity of AR-Vs 
at pro-proliferative genes in CRPC. To confirm this, 
CCNA2 expression was assessed in CWR22Rv1 cells 
depleted of either FOXA1, AR or AR-Vs in the presence 
and absence of Enzalutamide. As shown in Figure 6B, 
CCNA2 mRNA levels were unaffected by Enzalutamide 
Figure 4: A downstream repressive element in the AR gene controls AR-V expression. Chromatin immunoprecipitation 
(ChIP) experiments in CWR22Rv1 cells using AR (N-20) A. and FOXA1 B. antibodies to assess recruitment at intron 2 of the AR gene in 
response to 4 hour 10 nM DHT treatment. CWR22Rv1 cells depleted of FOXA1 were treated with Enzalutamide for 4 hours and subject 
to ChIP using FOXA1 C. and AR D. antibodies to assess recruitment to intron 2 of the AR gene. Fold enrichment is calculated in (D) to 
demonstrate loss of AR recruitment upon FOXA1 depletion (*denotes p = < 0.05 significance between siScr control and FOXA1 depletion). 
All data represents the mean of at least three independent experiments +/− SE (*denotes p-value < 0.05)
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treatment, indicating a dependency on AR-V-mediated 
transcription for CCNA2 expression, that was confirmed 
by AR-V knockdown (Supplementary Figure S14). 
Importantly, FOXA1 depletion attenuated CCNA2 
expression to levels equivalent to AR knockdown 
confirming our micro-array data. Moreover, using 
ChIP, we found that FOXA1 depletion diminished 
AR-V association at the CCNA2 promoter (Figure 6C) 
indicating the importance of FOXA1 as a pioneer factor 
for AR-V function at this loci.
Based on the results of our GSEA of shared AR-V/
FOXA1 genes, we next assessed the effect of AR-V and 
FOXA1 depletion on proliferation of CWR22Rv1 
cells grown in the presence and absence of DHT and 
Enzalutamide. Consistent with the role of AR-Vs 
in driving CWR22Rv1 cell growth [24], DHT and anti-
androgen treatment failed to effect proliferation of 
control transfected cells (siScr), while AR knockdown 
resulted in approximately 50% reduction in cell 
proliferation (Figure 6D). In keeping with the role of 
FOXA1 as a pioneer factor for AR-Vs, depletion of 
the FOXA1 protein down-regulated cell proliferation 
by over 60% suggesting that in addition to regulating 
the pro-proliferative activity of AR-Vs, FOXA1 may 
also control genes outside of the AR signalling cascade 
that are drivers of cell turnover. Using cell-cycle 
analysis, we found that FOXA1 depletion caused a 
cytostatic effect in CWR22Rv1 cells in which G1 phase 
is markedly elevated at the expense of S-, G2/M- and 
sub-G1- phases of the cell cycle (Figure 6E). In all, our 
data demonstrates that FOXA1 is a key regulator of 
AR-Vs in CRPC and supports the concept of targeting 
pioneer factor function as a treatment for advanced 
PC (see Figure 6F for diagrammatic representation of 
FOXA1-mediated regulation of AR-Vs in CRPC).
DISCUSSION
The development of new strategies to inactivate the 
AR signalling cascade in advanced CRPC is essential. 
The selection of cells displaying aberrant AR activity 
during first-line hormonal therapy that enable receptor 
function in castrate-like conditions is a hallmark of 
treatment failure and disease progression [1]. For 
Figure 5: AR-V- and FOXA1-target genes show considerable overlap. A. Venn diagrams of genes demonstrating 1.5-fold 
up- and down-regulation in response to AR and FOXA1 depletion in CWR22Rv1 cells grown in steroid-depleted conditions + 1 μM 
Enzalutamide. B. Validation of UBE2C, NKx3.1 and ATAD2 as AR-V- and FOXA1-co-regulated genes using quantitative PCR analysis 
of CWR22Rv1 cells depleted of AR or FOXA1 treated with and without Enzalutamide for 24 hours. C. Chromatin immunoprecipitation 
(ChIP) in CWR22Rv1 cells depleted of FOXA1 using an AR (N-20) antibody to assess AR-V binding to the UBE2C promoter (*denotes 
p = < 0.05 significance between siScr control and FOXA1 depletion). All data represents the mean of at least three independent experiments 
+/− SE (*denotes p-value < 0.05)
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example, mutation and non-androgenic stimulation of 
the AR enable persistence of receptor function in the 
presence of targeted therapy, such as the anti-androgen 
bicalutamide [21]. The development of the second 
generation anti-androgen Enzalutamide has had success in 
the clinic for treatment of CRPC, but efficacy is limited, 
in part, by the of appearance of an ARF876L mutation in 
the LBD that converts Enzalutamide to an agonist [9, 36]. 
Importantly, the complexity of first- and second-generation 
therapy resistance has increased with the key finding that 
alternative, constitutively active forms of the AR that lack 
the LBD, termed AR-Vs, are over-expressed in CRPC 
and hence are refractory to current anti-androgens [8, 29]. 
Indeed, detection of AR-Vs in circulating CRPC tumour 
cells has been used as a predictive biomarker for response 
to next-generation AR-targeting agents with patients 
demonstrating a positive correlation between AR-V 
expression and compromised drug efficacy [8].
The mechanisms that regulate AR-V generation in 
cells are well characterised with splicing aberrations and 
genomic deletion of exons 4–8, that encode the LBD, 
being largely responsible for the production of receptor 
variants in CRPC [27]. However, our understanding of 
regulatory processes that govern the functionality of 
AR-Vs in disease is limited, particularly with respect to 
transcriptional requirements of the variants for driving 
the androgenic signalling cascade in advanced PC. Using 
FL-AR as a paradigm of multimodal transcriptional 
Figure 6: AR-Vs and FOXA1 co-regulate pro-proliferative genes. A. Gene ontology analysis of co-regulated AR- and 
FOXA1-target genes shows significant enrichment of cell cycle and cell division associated genes. B. Impact of FOXA1 and AR 
knockdown on Cyclin A2 (CCNA2) expression in CWR22Rv1 cells grown in steroid-depleted media treated with 10 nM DHT or 1 μM 
Enzalutamide as measured by quantitative PCR. C. Chromatin immunoprecipitation (ChIP) was performed in CWR22Rv1 cells depleted 
of FOXA1 to assess AR-V recruitment to the CCNA2 promoter (*denotes p = < 0.05 significance between siScr control and FOXA1 
depletion). D. Proliferation assays to assess effect of AR or FOXA1 knockdown in CWR22Rv1 cells treated with 10 nM DHT or 1 μM 
Enzalutamide for 96 hours (* denotes p = < 0.05; ** denotes p = < 0.01 significance between siScr control and AR or FOXA1 knockdown, 
respectively). Representative western blots indicate AR and FOXA1 levels in response to protein knockdown. E. Cell cycle analysis using 
propidium iodide (PI) flow cytometry in CWR22Rv1 cells depleted of FOXA1 grown in the presence and absence of 1 μM Enzalutamide 
for 72 hours. All data represents the mean of at least three independent experiments +/− SE (*denotes p–value < 0.05). F. Diagrammatic 
representation of FOXA1-AR-V interplay in CRPC. Expression of AR-Vs are regulated by FOXA1 at the downstream repressive element 
(DRE) of the AR gene. FOXA1 also facilitates respective androgen-independent activation and repression of genes, such as CCNA2 and 
SRSF2 by AR-Vs.
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control, in which pioneer factors regulate chromatin 
deposition and activity of the receptor [14, 15], we 
focussed our study on the requirement of FOXA1 for 
AR-V activity in models of CRPC. Given that all reported 
AR-Vs contain the DNA-binding domain (DBD), that 
has been shown to be the site of FOXA1 interaction 
[37], combined with our initial findings that AR-Vs were 
constitutively chromatin-bound irrespective of hormonal/
anti-androgen status (Figure 1), suggested that FOXA1 
may co-operate with receptor variants to control their 
transcriptional output. Using FOXA1 siRNAs, we found 
that depletion of the pioneer factor elevated expression of 
PSA and KLK2 in CWR22Rv1 cells in both the presence 
and absence of DHT and Enzalutamide, and this was 
driven by up-regulated AR-V expression, specifically AR-
V7 and AR-1/2/3/2b. Using a combination of ChIP and 
quantitative mRNA analyses, we identified the existence 
of a negative feedback loop in CWR22Rv1 cells that is 
controlled by FOXA1 and acts to limit expression of AR-
Vs. Depletion of FOXA1 attenuates binding of receptor 
variants to a downstream repressor element in intron 
2 of the AR gene and hence selectively up-regulates 
expression of AR-Vs and, as a consequence, PSA and 
KLK2. Up-regulation of these genes has been recently 
reported in FOXA1-depleted LNCaP cells grown in the 
absence of androgens that occurs, in part, as a result of up-
regulated FL-AR expression and chromatin association at 
these genomic loci [19]. Moreover, global AR chromatin 
association was found to be reconfigured in the absence 
of FOXA1 to new AR binding sites (ARBSs), suggesting 
the pioneer factor may be repressive to FL-AR binding at 
discriminate cis-regulatory elements [19]. Our analyses of 
FOXA1 knockdown in LNCaP cells has confirmed some 
of these findings, but intriguingly, we have demonstrated 
that up-regulated PSA and KLK2 expression is insensitive 
to Enzalutamide and could be a result of elevated AR-V7, 
as well as FL-AR, expression (Supplementary Figure S15). 
It will be interesting to extrapolate these initial findings to 
include ChIP-Seq studies to interrogate the contribution, if 
any, of AR-Vs to the new FOXA1-independent ARBSs in 
LNCaP cells identified in Jin et al., (2014) [19].
A key observation from our CWR22Rv1 experiments 
was of selective up-regulation of AR-V7 and AR-1/2/3/2b, 
but not FL-AR, in response to FOXA1 knockdown 
(Figure 3), suggesting potential interplay between the 
splicing machinery and pioneer factor activity. A recent 
report has demonstrated that the binding of ASF2 and 
U2AF65 to splicing enhancer elements adjacent to exon 
3b of the AR gene regulates the generation of AR-V7 in 
both VCaP cells, and the androgen-independent LNCaP 
cell derivative LN95, in ADT conditions [33]. Importantly, 
depletion of these splicing factors down-regulated AR-V7 
levels without impacting on FL-AR mRNA indicating 
that discriminate spliceosomal function can be attributed 
to the processing of AR-Vs in models of CRPC. We 
speculate that flux to splicing factor expression and/or 
activity in response to FOXA1 knockdown could account 
for elevation of AR-Vs in CWR22Rv1 cells. Intriguingly 
ASF2 and U2AF65 mRNA was reduced upon pioneer 
FOXA1 depletion in our experiments (data not shown) 
suggesting that other splicing factors may contribute 
to AR-V production in these cells and this is being 
interrogated in our on-going studies.
Expression analysis demonstrated that 41% of 
AR-V target genes were also co-regulated by FOXA1 
indicating a considerable overlap and potential 
dependency of the receptor variants on pioneer 
factor activity for both AR-activated and—repressed 
transcriptomes. This was confirmed at several target 
genes, including UBE2C, NKX3.1, ATAD2 and CCNA2, 
in which depletion of either AR, AR-Vs or FOXA1 in 
Enzalutamide-treated CWR22Rv1 cells down-regulated 
their expression. Critically, knockdown of FOXA1 
attenuated enrichment of AR-Vs to cis-regulatory 
elements of UBE2C and CCNA2, indicating that the 
pioneer factor is required to facilitate constitutive 
receptor variant deposition at distinct genomic loci akin 
to the control of DHT-stimulated FL-AR recruitment 
to target genes in PC cells [16, 19]. We identified an 
80% overlap between our AR-V transcriptome and a 25 
gene signature reported by Hu et al., (2012) [34] to be 
regulated specifically by ectopically-expressed AR-V7 
in LNCaP cells, including UBE2C that is an established 
AR-V target gene [34]. Moreover, approximately 
52% of these overlapping genes were also regulated 
by FOXA1 in our data-set, suggesting considerable 
interplay between the receptor variants and FOXA1 
for transcriptional output. To further assess FOXA1 
function in CRPC, we compared our AR-V-target 
gene signature with that from a recent study in which 
an AR-V transcriptome was identified by subtractive 
analysis of total AR- and FL-AR-dependent gene-sets 
in CWR22Rv1 cells [35]. Consistent with the role of 
FOXA1 as a regulator of AR-Vs, we found that almost 
50% of the overlapping AR variant-target genes from 
our study and the one performed by Lu et al., (2015) 
[35] were also controlled by FOXA1. Importantly, 
however, we found only 20% concordance between 
the two independent AR-V target gene signatures 
that is likely to be a reflection of distinct, but valid 
experimental procedures that have been applied to 
delineate a specific AR-V transcriptional programme 
in the complex background of FL-AR expression. In 
contrast to selective FL-AR knockdown [35], we used 
steroid-depleted media supplemented with Enzalutamide 
to down-regulate FL-AR signalling and applied total AR 
knockdown to identify AR-V-driven genes. Differences 
in siRNA oligonucleotides as well as duration and 
efficacy of knockdown (48 hours in this study versus 
72 hours in [35]) is an important distinction that could 
promote significant variation in the two experimental 
outputs.
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There remains a paucity of agents/drugs available 
to attenuate receptor variant activity in the clinical 
setting hence components of the AR-V signalling 
network could represent novel therapeutic targets. 
The recent identification of the anti-helminthic drug 
Niclosamide as a selective destabiliser of AR-Vs in 
CWR22Rv1 cells and an AR-V7 expressing C4–2B cell 
line derivative suggests that selective targeting of these 
aberrantly functioning receptors is achievable at least in 
pre-clinical studies [38]. Consistent with this notion of 
blocking AR-V function, EPI-001 covalently binds to the 
AR N-terminus and has been shown to down-regulate 
both FL-AR- and AR-V-mediated signalling in vitro and 
in vivo [39]. Although a recent report has defined off-
target effects of EPI-001 outside of the AR signalling 
cascade in cell line models of disease [40], there remains 
major scope to utilise more refined agents targeting the 
unstructured transactivation domain of the receptor as a 
strategy for abrogating global AR function in advanced 
disease. We have shown that FOXA1 is a key regulator of 
CWR22Rv1 proliferation, in part, by controlling AR-V-
driven expression of cell cycle regulated genes, including 
CCNA2, CCNB1, CCNE2 and CDK1 suggesting that 
the pioneer factor represents an additional tractable 
therapeutic target in AR-V-expressing CRPC. In support 
of this, several studies have demonstrated up-regulated 
FOXA1 protein in advanced disease and knockdown 
attenuates growth of additional PC cell lines [16, 41]. 
Outside of PC, FOXA1 has been demonstrated to be 
a vital regulator of ER signalling in breast cancer and 
therefore is a bona fide therapeutic target in this disease 
setting [15, 42]. Targeting FOXA1 will be challenging, 
but inhibitors of an additional AR pioneer factor GATA2 
are available and have been successfully applied to 
several cell-line-based disease models, including PC 
[43]. In all, our data supports the concept that AR-V 
function is controlled by FOXA1 and provides additional 
justification for targeting pioneer factor activity in 
advanced CRPC.
MATERIALS AND METHODS
Transient siRNA transfection and cell treatments
CWR22Rv1, LNCaP and VCaP cells were 
maintained in RPMI1640 media (Sigma) supplemented 
with 10% foetal calf serum (FCS) and 5% L-glutamine at 
37°C. Transient transfection of FOXA1 and AR siRNAs 
(listed in Supplementary Table S5) was performed using 
Lipofectamine RNAiMax (Life Sciences). For 10 nM DHT, 
1 μM Bicalutamide and 1 μM Enzalutamide treatments, 
cells were grown in phenol red-free RPMI1640 (Life 
Sciences) containing 10% steroid-depleted FCS (Hyclone) 
for at least 24 hours prior to addition of compounds.
Quantitative PCR, western analyses, 
immunoprecipitation and chromatin extraction
Quantitative PCR was used to assess expression of 
AR-target genes (see Supplementary Table S3 for primer 
sequences) using cDNA generated from Trizol-mediated 
RNA extractions as described in [12]. Data represents the 
average of three independent experiments performed in 
triplicate. Western blotting was performed as described 
in [44] using the following antibodies; AR (N-20), AR 
(C-19), FOXA1, PARP-1 (Santa Cruz Biotechnology), 
AR-V7 (Precision Antibodies) and α-Tubulin (Sigma). 
Immunoprecipitation was conducted as described in [12] 
using the AR-V7 antibody. For chromatin preparation, 
CWR22Rv1 cells grown in the presence and absence of 
10 nM DHT, 1 μM Bicalutamide/1 μM Enzalutamide or 
transiently transfected with FOXA1 siRNAs, were subject 
to the extraction protocol described in [44].
Chromatin immunoprecipitation (ChIP) and 
FAIRE analyses
ChIP assays were performed as described in [44] 
utilising AR (N-20), AR (C-19) and FOXA1 antibodies 
(Santa Cruz Biotechnology). Quantitative PCR of resultant 
ChIP’d DNA was performed using primers to AR intron 
2 and AR-target genes (see Supplementary Table S3 
for sequences). For ChIP experiments investigating 
recruitment of AR and FOXA1 to target genes in response 
to FOXA1 depletion, CWR22Rv1 cells grown in steroid-
depleted media were transfected with either siFOXA1 
or siScr oligonucleotides for 48 hours prior to 24 hour 
stimulation with 1 μM Enzalutamide or vehicle control 
prior to chromatin preparation. Data is presented as the 
mean of at least 2 independent experiments. FAIRE was 
performed in both LNCaP and CWR22Rv1 cells grown in 
steroid-depleted media for 48 hours prior to 10 nM DHT 
treatment for 4 hours and formaldehyde cross-linking 
for 7 minutes. Cells were lysed and chromatin sonicated 
using the same ChIP protocol as above. Post-sonication, 
2 × phenol/chloroform extractions were performed before 
a final chloroform-isoamyl alcohol (24:1) vortex and spin 
at 12,000 g for 5 minutes. 1/10th volume of a 3 M sodium 
acetate (pH 5.2)/20 mg/ml glycogen mixture was added to 
supernatants together with 2 × volume of 100% ethanol to 
precipitate DNA at –20°C overnight. DNA was pelleted by 
centrifugation at 12,000 g for 30 minutes at 4°C, washed 
in 70% ethanol and air dried prior to resuspension in 
ChIP elution buffer (see [12]) and DNA clean-up using 
GeneElute mammalian genomic DNA miniprep kits 
(Sigma). Resultant DNA was analysed by quantitative 
PCR using primers listed in Supplementary Table S3. All 
statistical testing was performed using a student T-test in 
Microsoft Excel with * denoting p < 0.05.
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Cell proliferation and flow cytometry
CWR22Rv1 cells grown in steroid-depleted 
conditions +/− 10 nM DHT and 1 μM Enzalutamide 
post siFOXA1 and siAR transfection were trypsinised 
and counted individually using a haemocytometer. Data 
represents three independent experiments performed in 
quadruplicate. Cell cycle analysis using propidium iodide 
flow cytometry was performed as described in [45]. All 
statistical testing was performed using a student T-test in 
Microsoft Excel with * denoting p < 0.05.
Micro-array analysis
RNA was extracted from CWR22Rv1 cells grown 
in steroid-depleted media subjected to control, AR or 
FOXA1 knockdown for 24 hours prior to vehicle or 
1 μM Enzalutamide treatment for 24 hours. Samples 
were hybridised onto an Illumina HT12 v4 BeadChip 
Array (performed by The Wellcome Trust Centre for 
Human Genetics, Oxford University. Array processing, 
normalisation and quality control checks were performed 
using the R package ‘Lumi’. Probes intensity values 
were converted to VSD (variance stabilised data) using 
variance stabilizing transformation. The robust spline 
normalisation (RSN) was used as the array normalisation 
method. Outlier samples, poor quality probes (detection 
threshold < 0.01), and probes that are not detected 
at all in the remaining arrays were removed prior 
downstream analysis. The remaining probe (22,551) 
normalised intensity, VSD was used in the differential 
expression analysis. Differential expression analysis was 
performed using the R package ‘Limma’, and P values 
were adjusted to control the false discovery rate (FDR) 
using the Benjamini–Hochberg method. Gene ontology 
analysis was performed as described in [45].
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